SARS-CoV-2 mRNA vaccination within 100 days of ICI initiation was associated with increased overall survival in patients with NSCLC or metastatic melanoma
TUESDAY, Oct. 28, 2025 (HealthDay News) — For patients with certain types of advanced lung or skin cancer, administration of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA vaccine within 100 days of starting immune checkpoint inhibitors (ICIs) is associated with increased overall survival, according to a study presented at the annual meeting of the European Society for Medical Oncology, held from Oct. 17 to 21 in Berlin.
Adam J. Grippin, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center, and colleagues extracted data for patients with non-small cell lung cancer (NSCLC), melanoma treated with ICIs, and any tumor histology with biopsy samples evaluating programmed death-ligand 1 (PD-L1) to examine whether mRNA vaccines targeting nontumor antigens would sensitize tumors to ICIs.
The researchers found that for patients with NSCLC and metastatic melanoma, administration of a SARS-CoV-2 mRNA vaccine within 100 days of ICI initiation was associated with increased overall survival (adjusted hazard ratios, 0.51 and 0.34, respectively). With propensity score matching and among patients with immunologically cold tumors (tumor proportion score <1 percent), survival benefits were maintained. SARS-CoV-2 mRNA vaccination stimulated a surge in type I interferon in preclinical models; this prompted antigen-presenting cells to prime CD8 T cells to upregulate PD-L1 expression. Similar increases in type I interferon and antigen-presenting cell activation were seen in association with SARS-CoV-2 mRNA vaccination in humans, and increased PD-L1 expression was seen on tumor biopsies from patients with cancer.
“We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients,” coauthor Elias Sayour, M.D., Ph.D., from University of Florida Health, said in a statement.
Several authors disclosed ties to the biopharmaceutical industry; three hold patents related to the University of Florida-developed mRNA vaccines that are licensed by iOncology Inc.
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma 
Setmelanotide Beneficial in Acquired Hypothalamic Obesity 
